EHA 2026 | Insights from the AIEOP-BFM ALL trial: could blinatumomab replace high-dose chemotherapy in HR ALL?
Martin Schrappe, MD, FRCP, University Medical Center Schleswig-Holstein, Kiel, Germany, shares insights into the AIEOP-BFM ALL 2017 (NCT03643276) trial, which evaluates blinatumumab, a bispecific antibody, as a replacement for high-dose chemotherapy in pediatric patients with newly diagnosed high-risk acute lymphoblastic leukemia (HR ALL). Dr Schrappe highlights the superior efficacy of blinatumumab over standard chemotherapy, supporting a shift from intensive chemotherapy to immunotherapy in frontline treatment. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
